文献速递骨软组织肉瘤与黑色素瘤

横纹肌肉瘤诊断时的不确定肺结节:是否具有临床意义?欧洲儿童软组织肉瘤研究组报告

Indeterminate Pulmonary Nodules at Diagnosis in Rhabdomyosarcoma: Are They Clinically Significant? A Report From the European Paediatric Soft Tissue Sarcoma Study Group.
PubMed 文献 · J Clin Oncol · 2019-01-31

本研究纳入2005年9月至2013年12月诊断、登记于欧洲儿童软组织肉瘤研究组RMS 2005研究的316例假定非转移性儿童横纹肌肉瘤患者,比较诊断时存在不确定肺结节者与无结节者的事件无生存和总生存。结果显示两组5年事件无生存率和总生存率均无显著差异,诊断时的不确定肺结节不影响局限期患者的结局。

要点

  • 316例患儿中67例(21.2%)诊断时存在不确定肺结节,249例(78.8%)无肺结节。
  • 有结节组5年事件无生存率77.0%、总生存率82.0%,无结节组分别为73.2%和80.8%(P=.68和.76)。
  • 作者认为无需对诊断时存在不确定肺结节的局限期横纹肌肉瘤患者进行活检或上调分期。

核心结论

  • 本研究表明,诊断时的不确定肺结节不影响其他方面为局限期的横纹肌肉瘤患者的结局。
  • 作者认为无需对诊断时存在不确定肺结节的横纹肌肉瘤患者进行活检或上调分期。

研究设计与样本

  • 研究为欧洲儿童软组织肉瘤研究组(EpSSG)RMS 2005研究中的对照分析,纳入英国、法国、意大利和荷兰大型儿童肿瘤中心收治的假定非转移性横纹肌肉瘤患者。
  • 纳入患者诊断时间在2005年9月至2013年12月之间,且诊断时胸部计算机断层扫描(CT)可供复核。
  • 由当地放射科医生复核胸部CT,记录肺结节情况于标准化病例报告表。
  • 在EpSSG RMS 2005研究中,存在不确定肺结节的患者与无肺结节患者接受相同治疗,从而可用对数秩检验比较两组的事件无生存和总生存。
  • 共纳入316例患者。

主要发现

  • 67例患者(21.2%)影像学存在不确定肺结节,249例患者(78.8%)诊断时无明显肺结节。
  • 存活者(n=258)中位随访75.1个月。
  • 存在不确定结节的患者5年事件无生存率为77.0%(95%CI 64.8%至85.5%),总生存率为82.0%(95%CI 69.7%至89.6%)。
  • 诊断时无结节的患者5年事件无生存率为73.2%(95%CI 67.1%至78.3%),总生存率为80.8%(95%CI 75.1%至85.3%)。
  • 两组事件无生存和总生存比较的P值分别为.68和.76。

关键数值与推荐

  • 不确定肺结节定义为≤4个直径<5 mm的肺结节,或1个直径≥5且<10 mm的结节。
  • 存在不确定结节组5年事件无生存率77.0%(95%CI 64.8%至85.5%),无结节组73.2%(95%CI 67.1%至78.3%),P=.68。
  • 存在不确定结节组5年总生存率82.0%(95%CI 69.7%至89.6%),无结节组80.8%(95%CI 75.1%至85.3%),P=.76。

临床怎么用

  • 作者认为,对诊断时存在不确定肺结节的其他方面为局限期的横纹肌肉瘤患者,无需进行活检或上调分期。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the clinical significance of indeterminate pulmonary nodules at diagnosis (defined as ≤ 4 pulmonary nodules < 5 mm or 1 nodule measuring ≥ 5 and < 10 mm) in patients with pediatric rhabdomyosarcoma (RMS). PATIENTS AND METHODS: We selected patients with supposed nonmetastatic RMS treated in large pediatric oncology centers in the United Kingdom, France, Italy, and the Netherlands, who were enrolled in the European Soft Tissue Sarcoma Study Group (E pSSG) RMS 2005 study. Patients included in the current study received a diagnosis between September 2005 and December 2013, and had chest computed tomography scans available for review that were done at time of diagnosis. Local radiologists were asked to review the chest computed tomography scans for the presence of pulmonary nodules and to record their findings on a standardized case report form. In the E pSSG RMS 2005 Study, patients with indeterminate pulmonary nodules were treated identically to patients without pulmonary nodules, enabling us to compare event-free survival and overall survival between groups by log-rank test. RESULTS: In total, 316 patients were included; 67 patients (21.2%) had indeterminate pulmonary nodules on imaging and 249 patients (78.8%) had no pulmonary nodules evident at diagnosis. Median follow-up for survivors (n = 258) was 75.1 months; respective 5-year event-free survival and overall survival rates (95% CI) were 77.0% (64.8% to 85.5%) and 82.0% (69.7% to 89.6%) for patients with indeterminate nodules and 73.2% (67.1% to 78.3%) and 80.8% (75.1% to 85.3%) for patients without nodules at diagnosis ( P = .68 and .76, respectively). CONCLUSION: Our study demonstrated that indeterminate pulmonary nodules at diagnosis do not affect outcome in patients with otherwise localized RMS. There is no need to biopsy or upstage patients with RMS who have indeterminate pulmonary nodules at diagnosis.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Vaarwerk B, Bisogno G, McHugh K, et al. Indeterminate Pulmonary Nodules at Diagnosis in Rhabdomyosarcoma: Are They Clinically Significant? A Report From the European Paediatric Soft Tissue Sarcoma Study Group. J Clin Oncol. 2019. PMID: 30702969. doi:10.1200/JCO.18.01535

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。